Related Experiment Videos
Immunestimulation by 4-imino-1,3-diazabicyclo(3.1.0.)-hexan-2-on (BM 06.002)
Osterreichische Zeitschrift Fur Onkologie. Austrian Journal of Oncology
|January 1, 1977
Summary
The novel cancerostatic substance BM 06.002 impacts immune cells in mice. Low doses show no effect, while higher doses stimulate T-lymphocytes and antibody-producing B-cells, with a temporary suppression observed.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Cancerostatic agents require thorough investigation for their effects on the immune system.
- Understanding the immunomodulatory properties of novel compounds is crucial for therapeutic development.
Purpose of the Study:
- To evaluate the impact of the novel cancerostatic substance 4-imino-1,3-diazabicycle-(3.1.0.)-hexan-2-on (BM 06.002) on B-lymphocytes and T-lymphocytes in vivo.
- To determine dose-dependent effects of BM 06.002 on immunocompetence.
Main Methods:
- DBF1 mice were treated with varying concentrations of BM 06.002.
- Lymphocyte function was assessed using T-lymphocyte stimulation assays and the haemolytic plaque test for B-cells.
Main Results:
- BM 06.002 demonstrated no significant effect on immunocompetence at a low concentration (1 mg/kg).
- Higher concentrations (5-20 mg/kg) led to T-lymphocyte stimulation, sustained for over three weeks at 20 mg/kg.
- Antibody-producing B-cells showed stimulation on days 3 and 12 post-treatment.
- A transient suppression of lymphocyte functions was noted on day 5 in both T- and B-cell assays.
Conclusions:
- BM 06.002 exhibits dose-dependent immunomodulatory effects.
- The compound stimulates adaptive immune responses, specifically T-lymphocytes and B-cells, at higher concentrations.
- Further research is warranted to explore the therapeutic potential and detailed mechanisms of BM 06.002 in cancer treatment.